Napoli, 24-25 maggio 2019
Joint ESMO-AIOM-IQN Path session: the current status of biomarker testing in Europe
The aim of this session is to discuss with the different stakeholders (patients, medical oncologists, regulatory agencies, pharmas) the current status of access to and quality of biomarker testing in Europe.
- Organization and quality of biomarkers testing in Europe
- The relevance of biomarkers in precision oncology (ESMO)
- The access to biomarkers in Europe: the patients’ perspective (ECPC)
F. de Lorenzo
- The quality of biomarker testing in Europe (ESP)
- The pharmas’ view on biomarkers access and quality (EFPIA)
- The IARC collaboration for cancer classification and Research (IC3R)
Biomarkers for immunotherapy
In this session, the current status of biomarkers for immunotherapy will be discussed. An update of the current projects on PD-L1 and TMB testing form IQN Path and associated EQAs will be also presented.
- The evolving landscape of biomarkers for immune checkpoint inhibitors in thoracic oncology
- PD-L1 Project update report
- The DGP-QUIP PD-LI and TMB EQA program
The evolution of liquid biopsy in the management of cancer patients
In this session, the current status of the clinical implementation of liquid biopsies in clinical practice will be discussed.
- Tumor heterogeneity and liquid biopsy
- Summary of IQN Path cfDNA testing in Lung Cancer EQA 2018
The relevance of fusion genes in cancer treatment and the challenge for testing
This session will address the new treatment options for patients carrying fusion genes and highlight the challenges for testing fusions in cancer.
- Fusion genes as targets for therapeutic intervention in cancer
- Assessment of fusion genes: pros and cons of the different testing strategies
- The IQN Path proposal for a pilot EQA scheme for fusion genes testing
BRCA and HRD testing in cancer
- Implications of BRCA testing in cancer